Intravitreal triamcinolone acetonide in exudative age-related macular degeneration

Retina

Volumn 20, Issue 3, 2000, Pages 244-250

  Danis, Ronald P ^a,b   Ciulla, Thomas A ^a   Pratt, Linda M ^a   Anliker, Wayne ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis inhibition; Choroidal neovascularization; Macular degeneration; Triamcinolone acetonide

Indexed keywords

ANTIGLAUCOMA AGENT; FLUORESCEIN; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 0033944912     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200003000-00004     Document Type: Article

References (14)

1. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol 1986;104:694-701.
2. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 1999;117:1329-1345.
3. Schlaegel TF. Ocular Histoplasmosis. New York: Grune & Stratton, 1977.
4. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
5. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985; 103:1567-1569.
6. McCuen BWD, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-788.
7. Danis RP, Bingaman DP, Yang Y, Ladd L. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-2104.
8. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-816.
9. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell D. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34-40.
10. Folkman J, Ingber D. Angiostatic steroids. Ann Surg 1987; 206:374-382.
11. Proia A, Hirakata A, McInnes J, Scroggs M, Parikh I. The effect of angiostatic steroids and B-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res 1993;57:693-698.
12. Oh H, Takagi H, Takagi T, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-1898.
13. Penfold P, Gyory J, Hunyor A, Billson F. Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust NZ J Ophthalmol 1995;23:293-298.
14. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18-month follow up. Aust NZ J Ophthalmol 1998;26:277-281.